Endocyte, Inc. (ECYT) Touches $1.92 Low on Jun, 2, Regeneron Pharmaceutical (REGN) Shorts Raised By 6.59%

June 2, 2017 - By Kurt Siggers

The stock of Endocyte, Inc. (NASDAQ:ECYT) reached all time low today, Jun, 2 and still has $1.80 target or 6.00% below today’s $1.92 share price. This indicates more downside for the $87.31 million company. This technical setup was reported by Barchart.com. If the $1.80 PT is reached, the company will be worth $5.24M less. About 1.17 million shares traded or 145.82% up from the average. Endocyte, Inc. (NASDAQ:ECYT) has declined 24.78% since June 2, 2016 and is downtrending. It has underperformed by 41.48% the S&P500.

Regeneron Pharmaceutical Incorporated (NASDAQ:REGN) had an increase of 6.59% in short interest. REGN’s SI was 3.05 million shares in June as released by FINRA. Its up 6.59% from 2.86M shares previously. With 910,900 avg volume, 3 days are for Regeneron Pharmaceutical Incorporated (NASDAQ:REGN)’s short sellers to cover REGN’s short positions. The SI to Regeneron Pharmaceutical Incorporated’s float is 3.92%. About 157,995 shares traded. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has risen 17.40% since June 2, 2016 and is uptrending. It has outperformed by 0.70% the S&P500.

Investors sentiment increased to 1.38 in Q4 2016. Its up 0.49, from 0.89 in 2016Q3. It improved, as 7 investors sold Endocyte, Inc. shares while 22 reduced holdings. 13 funds opened positions while 27 raised stakes. 14.71 million shares or 4.95% less from 15.48 million shares in 2016Q3 were reported. Concannon Wealth Mngmt Ltd Co invested in 0.09% or 32,639 shares. Jpmorgan Chase And Communications holds 0% of its portfolio in Endocyte, Inc. (NASDAQ:ECYT) for 789,735 shares. Bridgeway Capital Management has 195,800 shares. Stifel Fincl has invested 0% in Endocyte, Inc. (NASDAQ:ECYT). Jacobs Levy Equity Inc has invested 0% in Endocyte, Inc. (NASDAQ:ECYT). Sterling Capital Mgmt Ltd accumulated 30,273 shares or 0% of the stock. State Common Retirement Fund owns 54,171 shares. Vanguard invested in 0% or 1.49 million shares. Blackrock Institutional Tru Na holds 0% or 517,159 shares in its portfolio. Hilltop owns 10,720 shares or 0.01% of their US portfolio. Kcg Incorporated has invested 0% in Endocyte, Inc. (NASDAQ:ECYT). Blackrock Inc stated it has 8,763 shares. Anson Funds Lp has 0.09% invested in Endocyte, Inc. (NASDAQ:ECYT). 1St Source Bankshares holds 32,942 shares. Schwab Charles Management Inc owns 0% invested in Endocyte, Inc. (NASDAQ:ECYT) for 110,071 shares.

Among 2 analysts covering Endocyte (NASDAQ:ECYT), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Endocyte had 3 analyst reports since August 5, 2015 according to SRatingsIntel. As per Thursday, January 21, the company rating was initiated by Credit Suisse. The company was maintained on Wednesday, August 5 by RBC Capital Markets. The stock of Endocyte, Inc. (NASDAQ:ECYT) earned “Outperform” rating by RBC Capital Markets on Wednesday, November 4.

Endocyte Inc. is a biopharmaceutical company. The company has market cap of $87.31 million. The Firm is engaged in developing therapies for the treatment of cancer and inflammatory diseases. It currently has negative earnings. The Firm uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics.

Investors sentiment increased to 1.25 in 2016 Q4. Its up 0.29, from 0.96 in 2016Q3. It improved, as 48 investors sold Regeneron Pharmaceuticals Inc shares while 151 reduced holdings. 60 funds opened positions while 188 raised stakes. 70.27 million shares or 1.15% less from 71.09 million shares in 2016Q3 were reported. Cleararc Capital owns 1,845 shares. Bessemer Gru invested 0% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Waldron Limited Partnership holds 0.11% or 874 shares. Verition Fund Management Limited Liability Co owns 2,618 shares for 0.08% of their portfolio. Moreover, State Of Wisconsin Board has 0.06% invested in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 39,992 shares. Laurion Cap Mgmt Limited Partnership holds 1,900 shares or 0.01% of its portfolio. Envestnet Asset Inc owns 0.02% invested in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 15,974 shares. Founders Ltd Com invested in 677 shares or 0.13% of the stock. Tiaa Cref Invest Mngmt Limited Liability accumulated 253,925 shares. Janney Montgomery Scott Ltd invested 0.01% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Endurant Cap Management L P invested in 0.33% or 2,200 shares. Westpac Bk has invested 0% in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Jgp Glob Gestao De Recursos Ltda invested 0.59% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN). Adage Capital Ptnrs Group Ltd accumulated 13,310 shares or 0.01% of the stock. Fil Ltd holds 0.04% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 35,840 shares.

Since December 12, 2016, it had 1 insider purchase, and 4 selling transactions for $25.09 million activity. $400,000 worth of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares were sold by BROWN MICHAEL S. 3,000 shares were sold by BAKER CHARLES A, worth $1.18 million. VAGELOS P ROY sold $4.26M worth of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on Thursday, May 25. The insider Sanofi bought 87,298 shares worth $32.27 million.

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical firm that discovers, invents, develops, makes and commercializes medicines for the treatment of serious medical conditions. The company has market cap of $50.94 billion. The Firm commercializes medicines for eye diseases, high low-density lipoprotein cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. It has a 56.8 P/E ratio. The Company’s marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.

Among 22 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 12 have Buy rating, 0 Sell and 10 Hold. Therefore 55% are positive. Regeneron Pharmaceuticals Inc. had 49 analyst reports since July 28, 2015 according to SRatingsIntel. On Tuesday, March 8 the stock rating was reinitiated by Brean Capital with “Buy”. The rating was upgraded by Vetr on Friday, August 21 to “Buy”. Chardan Capital Markets upgraded it to “Neutral” rating and $350 target in Monday, December 12 report. Chardan Capital Markets upgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) rating on Tuesday, February 16. Chardan Capital Markets has “Neutral” rating and $375 target. RBC Capital Markets maintained Regeneron Pharmaceuticals Inc (NASDAQ:REGN) rating on Thursday, November 5. RBC Capital Markets has “Outperform” rating and $676 target. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has “Outperform” rating given on Friday, February 5 by Leerink Swann. The stock of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has “Buy” rating given on Friday, May 5 by Canaccord Genuity. Chardan Capital Markets downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) rating on Wednesday, March 16. Chardan Capital Markets has “Sell” rating and $325 target. The firm has “Sell” rating given on Wednesday, August 5 by UBS. Zacks upgraded the stock to “Hold” rating in Tuesday, August 11 report.